Skip to main content
NCBI home page
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2015 Aug;482:72–78. doi: 10.1016/j.virol.2015.03.015

Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection

Petra Mlcochova a, Luis Apolonia b, Silvia F Kluge c, Aishwarya Sridharan a, Frank Kirchhoff c, Michael H Malim b, Daniel Sauter c, Ravindra K Gupta a,⁎
PMCID: PMC4503796  PMID: 25827531

Abstract

Heterosexual HIV-1 transmission has been identified as a genetic bottleneck and a single transmitted/founder (T/F) variant with reduced sensitivity to type I interferon initiates productive infection in most cases. We hypothesized that particularly active accessory protein(s) may confer T/F viruses with a selective advantage in establishing HIV infection. Thus, we tested vpu, vif and nef alleles from six T/F and six chronic (CC) viruses in assays for 9 immune evasion activities involving the counteraction of interferon-stimulated genes and modulation of ligands known to activate innate immune cells. All functions were highly conserved with no significant differences between T/F and CC viruses, suggesting that these accessory protein functions are important throughout the course of infection.

Keywords: HIV, Vpu, Nef, Vif, Accessory, Acute, Chronic

Highlights

  • •

    Transmitted/founder viruses are known to be relatively interferon resistant.

  • •

    Transmitted/founder HIV-1 viruses have fully functional accessory genes Vpu, Vif and Nef.

  • •

    Vpu, Vif and Nef functions do not appear to differ between acute and chronic infection.

Introduction

Studies have defined a genetic ‘bottleneck’ at mucosal HIV-1 transmission with a single inferred variant initiating peripheral viremia in most cases (Baalwa et al., 2013; Fenton-May et al., 2013; Haaland et al., 2009; Ochsenbauer et al., 2012; Parrish et al., 2013; Salazar-Gonzalez et al., 2009). In particular it has been noted that transmitted founder (T/F) Envelope proteins are R5 tropic with both increased sensitivity to broadly neutralizing antibodies (Wilen et al., 2011) and reduced ability to interact with maraviroc-bound CCR5 compared to viruses isolated from chronic infection (Parker et al., 2013). Furthermore, preferential transmission of ancestral as opposed to contemporary strains in donor individuals has been reported (Redd et al., 2012), suggesting specific viral determinants for sexual transmission that differ from determinants for propagation of chronic infection. Intriguingly, it has been reported that T/F viruses are less restricted by interferon (IFN) in primary T cells than chronic controls (Fenton-May et al., 2013; Parrish et al., 2013).

Lentiviral accessory proteins have evolved the ability to mitigate the detrimental effects of an IFN-induced antiviral immune response by interfering with various host immunity factors (Harris et al., 2012; Moll et al., 2010; Shah et al., 2010). For example, HIV-1 Vpu and Vif counteract the IFN-inducible restriction factors tetherin/BST-2/CD317 (Neil et al., 2008; Van Damme et al., 2008) and APOBEC3D/F/G, respectively (Bishop et al., 2004; Hultquist et al., 2011; Sheehy et al., 2002; Zheng et al., 2004). Vpu also prevents expression of IFN and IFN-stimulated genes by inhibiting the activation of NF-κB (Bour et al., 2001; Sauter et al., 2015), and Nef is known to modulate a range of host immune receptors including CD4 and MHC molecules (Kirchhoff, 2010).

We hypothesized that accessory gene(s) from T/F viruses confer advantages to establishment and early propagation of HIV-1 infection either through counteraction of IFN-stimulated genes or modulation of ligands known to activate NK, NKT and other immune cells. We therefore directly compared functional activities of the accessory proteins Vpu, Vif and Nef from six T/F and six CC viruses (see Table 1 for patient characteristics and Supplementary Figs. 1–3 for multiple sequence alignments).

Table 1.

Origins and characteristics of viruses used in this study.

Virus Country of origin Gender Transmission route Fiebig stage Viral load at isolation Cd4 count at isolation Coreceptor tropsim TF/CC HIV-1 subtype
ZM246F Zambia F Heterosexual II 10,013,800 NA R5 TF C
ZM247F Zambia F Heterosexual II 10,823,500 NA R5 TF C
ZM249M Zambia M Heterosexual IV >2,000,000 NA R5 TF C
CH040 USA M MSM II 2,197,248 NA R5 TF B
WITO USA M Heterosexual II 325, 064 NA R5 TF B
CH077 USA M MSM II/III 394, 649 NA R5/X4 TF B
CH432 Malawi M Heterosexual NA 40,570 261 R5 CC C
CH457 Tanzania F Heterosexual NA 234,671 450 R5 CC C
CH534 South Africa F Heterosexual NA NA NA NA CC C
RHGA USA M MSM NA 50,000 571 R5 CC B
WARO USA F MSM NA 16,758 598 R5 CC B
STCOr1 USA M MSM NA 67,964 796 R5/X4 CC B
Open in a new tab

Key: MSM: men who have sex with men; TF – transmitted/founder virus; CC- Chronic virus; NA – not available; Feibig stage as described previously (Fiebig et al., 2003)

Results

Counteraction of tetherin/BST-2/CD317 and NF-κB activation by Vpu

Vpu proteins from T/F and CC viruses were tested for their ability to increase virion release by counteracting tetherin/BST-2/CD317. Tetherin serves as a physical tether between viral and cellular membranes and inhibits the egress of budding virions from infected cells. All Vpus were expressed (Fig. 1A) and enabled efficient virus release from tetherin expressing HEK293T cells. Anti-tetherin activity was similar for Vpus from T/F and CC viruses (p=0.51, Fig. 1B), consistent with a previous study demonstrating conservation of tetherin antagonism over extended periods in chronically infected patients (Pickering et al., 2014).

Fig. 1.

Fig. 1

Open in a new tab

Vpu-mediated counteraction of tetherin, inhibition of NF-κB activation and downmodulation of CD4, NTB-A and CD1d. (A) Immunoblot showing expression of T/F and CC Vpu proteins in HEK293T cells transfected with pCG vpu IRES eGFP expression constructs. An antibody against AU-1 was used to detect C-terminally tagged Vpu. (B) HEK293T cells were co-transfected with expression vectors for HIV-1 Gag-Pol, VSV-G, a modified HIV genome encoding firefly luciferase, Vpu and tetherin or an empty vector control. 48 h post-transfection, viral supernatants were used to infect TZM-bl cells and luciferase activity was measured 24 h post-infection. Infectious virus yield in the presence of Vpu was normalized to that in the presence of empty vector (vector control). (C and D) HEK293T cells were co-transfected with Vpu expression plasmids, along with plasmid expressing an NF-κB-dependent firefly luciferase reporter construct and a pTAL promoter gaussia luciferase plasmid for normalization, and either a plasmid expressing (C) human tetherin or (D) a constitutively active mutant of IKKβ. 40 h post- transfection, dual luciferase assays were performed. Firefly luciferase signals were divided by the corresponding gaussia luciferase signals and normalized to the vector control. (E–J) HEK293T cells were transfected with (E and F) CD4 (G and H) NTB-A or (I and J) CD1d expression vectors and plasmids expressing eGFP alone or together with Vpu. Two days post-transfection CD4, NTB-A or CD1d surface expression was detected by fluorophore-conjugated antibodies and examined by flow cytometry. Mean fluorescence intensities were normalized to the control construct expressing only eGFP (vector control). Each data point represents one vpu allele. The mean of three independent experiments ± sd is shown. In all experiments, unpaired Student׳s t test was performed to examine differences between T/F and CC viruses. (E,G and I) Examples of primary experimental data from flow cytometry for one T/F and CC Vpu.

Tetherin does not only restrict virion release but also acts as an innate sensor activating NF-κB-dependent expression of type I IFN and IFN-stimulated genes (Galao et al., 2012). We therefore investigated whether T/F Vpus are more efficient in blocking tetherin signaling than Vpus from CC viruses. A dual luciferase reporter assay in HEK293T cells revealed that all Vpus efficiently inhibited the activation of NF-κB with no significant differences between the T/F and CC groups (p=0.81, Fig. 1C). Since Vpu has also been reported to block activation of NF-κB independently of tetherin (Bour et al., 2001; Sauter et al., 2015), we repeated the experiment using a constitutively active mutant of IKKβ instead of tetherin as the inducer. Again, T/F and CC Vpus suppressed NF-κB activation to similar degrees (p=0.31, Fig. 1D).

Cell surface downregulation of CD4, NTB-A and CD1d by Vpu

Besides counteracting tetherin and inhibiting NF-κB activation, Vpu also decreases cell surface expression of CD4, NTB-A and CD1d. While downmodulation of CD4 prevents superinfection and enables the release of fully infectious progeny virions from infected cells (Kimura et al., 1994; Lama et al., 1999; Wildum et al., 2006), downmodulation of NTB-A and CD1d has been suggested to protect HIV-1 infected cells from NK or NKT cell mediated killing, respectively (Moll et al., 2010; Shah et al., 2010). Using flow cytometry, we monitored expression of these receptors on the surface of HEK293T cells transfected with Vpu or a vector control. Vpu reduced surface levels of all three receptors as expected, without significant differences between T/F and CC viruses (CD4: p=0.84, NTB-A: p=0.61, CD1d: p=0.34, Fig. 1E–J).

Counteraction of APOBEC3F/G by Vif

The accessory protein Vif induces the ubiquitination and subsequent degradation of the restriction factors APOBEC3DF/G/H to prevent their incorporation into viral particles (Bishop et al., 2004; Hultquist et al., 2011; Sheehy et al., 2002). APOBEC3F/G are cytidine deaminases, inhibiting HIV-1 replication through G to A hypermutation of viral cDNA as well as direct inhibition of reverse transcription itself (Gillick et al., 2013). We analyzed the activity of T/F and CC Vif proteins against human APOBEC3F and APOBEC3G by co-transfecting HEK293T cells with plasmids encoding vif-deficient HIV-1 along with APOBEC3F or APOBEC3G and vif alleles/empty plasmid. As Vif expression/ stability varied between alleles tested, the amount of Vif expression plasmid was modified in order to achieve similar amounts of Vif protein in the producer cells (Fig. 2A). Under these conditions the infectivity of supernatant viruses was determined, revealing that Vifs from T/F and CC viruses have equivalent activity against APOBEC3F and APOBEC3G (Fig. 2B and C).

Fig. 2.

Fig. 2

Open in a new tab

Vif-mediated counteraction of APOBEC3F and APOBEC3G. HEK293T cells were transfected with plasmids encoding NL4-3 Δvif, APOBEC3F or G and HA-tagged Vif proteins. 48 h post-transfection, producer cells and supernatants were harvested. (A) Expression of Vif proteins in producer cells was assessed by standard immunoblot. (B and C) Virion infectivity of supernatants generated in the presence of APOBEC3F (B) or APOBEC3G (C) was determined using TZM-bl indicator cells. Luciferase values were normalized to controls without Vif (vector control). The mean of four independent replicates ±sd is shown.

Cell surface downregulation of CD4, CD28 and MHC class I by Nef

The accessory protein Nef downregulates various cell surface proteins including CD4, MHC class I and CD28 to escape immune surveillance (Garcia and Miller, 1991; Schwartz et al., 1996; Swigut et al., 2001) and may thus also be involved in the reduced sensitivity of T/F viruses to IFN. CD4 and CD28 downregulation were analyzed by transient transfection of HEK293T cells with vectors expressing Nef and either CD4 or CD28. All Nef proteins were efficiently expressed (Fig. 3A) and reduced surface expression of both receptors with no significant differences between T/F and CC viruses (CD4: p=0.71, CD28: p=0.76, Fig. 3B–E). To explore MHC class I downregulation, a HeLa cell line expressing HLA-B⁎27 was transfected with different nef alleles and MHC class I cell surface expression was analyzed by FACS 48 h post-transfection. Nef proteins of both groups of viruses downmodulated MHC class I to a similar extent (p=0.22, Fig. 3F and G).

Fig. 3.

Fig. 3

Open in a new tab

Nef-mediated downmodulation of CD4, CD28, MHC class I and enhancement of virion infectivity. (A) Immunoblot showing expression of T/F and CC Nef proteins in HEK293T cells transfected with pCG_nef IRES eGFP expression constructs. An antibody against AU-1 was used to detect C-terminally tagged Nef. (B–E) HEK293T cells were transfected with (B and C) CD4 or (D and E) CD28 expression vector and constructs expressing eGFP alone or together with Nef. Two days post-transfection CD4 or CD28 expression was detected by flow cytometry. Mean fluorescence intensities were normalized to the control construct expressing only eGFP (vector control). (F and G) MHC class I downregulation using HeLa.B27 cells transfected with constructs expressing eGFP alone or together with Nef. Two days post-transfection MHC I expression was analyzed by flow cytometry as described above. (H) Virion infectivity enhancement by Nef was measured using HEK293T cells co-transfected with HIV-1 NL4-3 and eGFP Nef. Supernatants were harvested 48 h post-transfection and p24-normalized virus was used to infect TZM-bl cells. Infectivity was normalized to the control construct expressing no nef allele (vector control). The mean of at least three independent experiments ±sd is shown. (B,D and F) Example of primary experimental data from flow cytometry for one T/F and CC Nef.

Nef-mediated enhancement of virion infectivity

It has been shown that HIV-1 virion infectivity is reduced in the absence of a functional nef gene (Aiken and Trono, 1995; Chowers et al., 1994). We thus tested the effect of Nef proteins on virion infectivity by transfecting HEK293T cells with nef alleles and nef-deficient HIV-1 NL4-3. Supernatants harvested two days post-transfection were used to infect indicator TZM-bl cells with normalized amounts of p24. Despite variation between individual Nef proteins in their ability to enhance virion infectivity, there was no statistical difference when T/F and CC Nefs were compared (p=0.77, Fig. 3H).

Discussion

In summary, our results show that established functions of the accessory proteins Vpu, Vif and Nef are conserved across T/F and CC viruses. Specifically, our results from transient expression studies suggest that the increased IFN resistance of newly transmitted HIV-1 strains is not the result of a particularly efficient Vpu-mediated inhibition of NF-κB activation or counteraction of the restriction factors tetherin and APOBEC3F/G. An important limitation is that viral proteins were not expressed from a provirus in our experiments, and therefore it is possible that in vivo expression may differ.

The identification of traits that are shared by T/F viruses may ultimately provide novel targets for strategies aiming to prevent the acquisition of HIV-1 at mucosal surfaces. Thus, further analyses of accessory viral gene function in primary human cells and systematic comparison of other HIV-1 gene products are highly warranted to decipher the reason(s) for the increased IFN resistance and selection advantage of T/F viruses during transmission and acute infection.

Materials and methods

Cell culture and transfections

HEK293T, TZM-bl and HeLa.B27 cells were grown under standard conditions in Dulbecco׳s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 120 mg/ml streptomycin, 120 mg/ml penicillin and 2 mM l-glutamine. Cells were transfected using the calcium-phosphate precipitation method, polyethyleneimine (PEI) or Fugene 6 (Roche Applied Science).

Expression vectors

Vpu, Nef, CD1d, CD4, NTB-A (transcript variant 2) and BST-2/tetherin alleles were cloned into the CMV-promoter-based pCG expression vector, vpu and nef encoding vectors co-expressing eGFP or DsRed via an IRES as previously described (Sauter et al., 2009). CD28 was cloned into in a pcDNA3.1+ vector. HA-tagged subtype B and C Vif alleles were amplified from transmitted/founder and chronic full-length IMCs (infectious molecular clones) kindly provided by Beatrice Hahn and cloned into pcDNA3.1 using NotI and XhoI restriction sites. The plasmids encoding T7-A3F/G have been previously described (Apolonia et al., 2015). The firefly luciferase reporter plasmid containing three NF-κB binding sites as well as the constitutively active mutant of IKKβ were kindly provided by Bernd Baumann. A minimal promoter gaussia luciferase construct was purchased from Clontech (#631909) and used for normalization. It contains the TATA-like promoter (pTAL) region from the Herpes simplex virus thymidine kinase (HSV-TK) that is not responsive to NF-κB.

Western blotting

Protein expression was assessed by standard immunoblots using anti AU-1 antibody (bs-2114R, Bioss) to detect AU1 tagged Vpu and Nef proteins or anti HA (3F10, Roche) to identify HA-tagged Vif. Anti-HSP90 (H114, Santa Cruz Biotechnology) and anti-actin antibody (AC-15, Abcam) were used to detect the loading control proteins.

Flow cytometry

To determine the effect of Vpu on CD1d or NTB-A, HEK293T cells were transfected with 1 μg of the CD1d or NTB-A expression vector and 5 μg of pCG_IRES eGFP constructs expressing eGFP alone or together with Vpu. Two days post-transfection CD1d or NTB-A expression was examined by FACS analysis, essentially as described previously (Sauter et al., 2013). A phycoerythrin-conjugated anti-CD1d antibody (BD 550255) or an APC-conjugated anti-SLAM6 antibody (R&D FAB19081A) were used for staining. Fluorescence of stained cells was detected by two-color flow cytometry and Vpu-mediated down-modulation of the respective protein was calculated. Briefly, the mean fluorescence intensities were determined for cells showing specific ranges of eGFP expression. The fluorescence values obtained for cells transfected with the control construct expressing only eGFP was compared with the corresponding number obtained for cells coexpressing Vpu and eGFP to determine the efficiency of CD1d or NTB-A down-modulation.

To determine the effect of Vpu and Nef on CD4, HEK293T cells were transfected with 0.05 μg of the CD4 expression vector and 0.15 μg of pCG_IRES eGFP constructs expressing eGFP alone or together with Vpu or Nef. Two days post- transfection CD4 expression was examined by FACS analysis. A PE/Cy5 anti-human CD4 Antibody (BioLegend) was used for staining. Fluorescence of stained cells was detected by two-color flow cytometry and quantified as described above.

To determine the effect of Nef on CD28, HEK293T cells were transfected with 1 μg of the CD28 expression vector and 0.15 μg of pCG_IRES eGFP constructs expressing eGFP alone or together with Nef. Two days post-transfection CD28 expression was examined by FACS analysis. APC-conjugated anti-human CD28 antibody (CD28.2, BD Biosciences) was used for staining.

To determine the effect of Nef on MHC I, HeLa.B27 cells [a kind gift from Anthony Antoniou] were transfected with 0.5 μg of pCG_IRES eGFP constructs expressing eGFP alone or together with Nef. Two days post-transfection MHC I expression was examined by FACS analysis. A PE/Cy5 anti-human HLA-A,B,C antibody, clone W6/32 (BioLegend) was used for staining. Fluorescence of stained cells was detected by two-color flow cytometry and quantified as described above.

NF-κB reporter assay

Transfections for luciferase assays were performed in 96-well plates and each transfection was performed in triplicate as described before (Sauter et al., 2013). Briefly, Vpu expression plasmids (100 ng) were transfected in HEK293T cells along with a plasmid expressing human tetherin or a constitutively active mutant of IKKβ (40 ng), an NF-κB-dependent firefly luciferase construct (100 ng) and a pTAL promoter gaussia luciferase reporter plasmid (25 ng). 40 h post-transfection, dual luciferase assays were performed. Firefly luciferase signals were normalized to the corresponding gaussia luciferase signals.

Luciferase reporter virus assay

HEK293T cells were co-transfected with 0.3 μg of p8.91 HIV-1 gag-pol expression vector, 0.3 μg VSV-G, and 0.45 μg of pCSLUCW retroviral expression vector encoding luciferase. For tetherin counteraction experiments, 0.25 μg of T/F or CC Vpu constructs were co-transfected with 0.05 μg of tetherin, or empty vector (pcDNA3.1). 48 h post-transfection, viral supernatants were harvested, filtered using 0.45 µm pore-sized filters and used to infect TZM-bl cells. Luciferase activity of the TZM-bl cells was measured 24 h post-infection using the Steady Glo Firefly Luciferase assay (Promega) and GloMax96 Luminometer (Promega).

Nef infectivity assay

HEK293T cells were cotransfected with 0.4 μg pBR_HIV-1 M NL4-3 (nef STOP) and 2 μg of pCG_Nef IRES eGFP in six well plates using the Calcium phosphate method. Virus was harvest from supernatant 48 h post-transfection and normalized using p24Gag ELISA. Normalized virus was used to infect indicator TZM-bl cells and β-galactosidase activity measured 72 h post-infection using Gal-screen substrate (Applied Biosystems, USA).

A3F/G restriction assay

HEK293T cells were co-transfected with vif-deficient NL4-3 (Phalora et al., 2012) and T7-A3F/G (Apolonia et al., 2015) at a 1:1 ratio. Cells were also co-transfected with plasmids encoding HA-tagged Vif proteins from T/F and CC viruses. 48 h after transfection, supernatants containing viruses were harvested, filtrated through a 45 μm pore-sized filter and quantified using a p24Gag ELISA (Perkin Elmer). Viruses were then used to infect indicator TZM-bl cells and luciferase activity was measured 48 h post-infection. Producer cells were lysed in RIPA buffer (50 mM Tris–HCl pH 7.4, 100 mM NaCl, 1 mM MgCl2, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate). Protein expression was assessed by standard immuno blot, anti HA (3F10, Roche) to identify HA-tagged Vif and anti-HSP90 (H114, Santa Cruz Biotechnology). Proteins were then detected by Li-cor Odyssey infrared imaging using IRDye800CW or IRDye 680LT-labeled secondary antibodies.

Acknowledgments

T/F and CC infectious molecular clones were kindly provided by Drs Beatrice Hahn and Robert Doms. The firefly luciferase reporter plasmid containing three NF-κB binding sites as well as the constitutively active mutant of IKKβ were kindly provided by Bernd Baumann. We would like to thank Susanne Engelhart for assistance with experiments. The HeLa.B27 cell line was a kind gift from Anthony Antoniou. LA and MHM were supported by the U.K. Medical Research Council. (Grant no. G1000196) RKG was supported by a Wellcome Trust Fellowship (WT093722MA).

Footnotes

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.virol.2015.03.015.

Appendix A. Supplementary materials

Supplementary Figure 1: amino acid alignment of Vpu alleles used in this study.

mmc1.doc (49.9KB, doc)

Supplementary Figure 2: amino acid alignment of Vif alleles used in this study

mmc2.doc (85.8KB, doc)

Supplementary Figure 3: amino acid alignment of Nef alleles used in this study

mmc3.doc (97KB, doc)

References

  1. Aiken C., Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J. Virol. 1995;69:5048–5056. doi: 10.1128/jvi.69.8.5048-5056.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Apolonia L., Schulz R., Curk T., Rocha P., Swanson C.M., Schaller T., Ule J., Malim M.H. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1. PLoS Pathog. 2015;11:e1004609. doi: 10.1371/journal.ppat.1004609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baalwa J., Wang S., Parrish N.F., Decker J.M., Keele B.F., Learn G.H., Yue L., Ruzagira E., Ssemwanga D., Kamali A., Amornkul P.N., Price M.A., Kappes J.C., Karita E., Kaleebu P., Sanders E., Gilmour J., Allen S., Hunter E., Montefiori D.C., Haynes B.F., Cormier E., Hahn B.H., Shaw G.M. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013;436:33–48. doi: 10.1016/j.virol.2012.10.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. CB. 2004;14:1392–1396. doi: 10.1016/j.cub.2004.06.057. [DOI] [PubMed] [Google Scholar]
  5. Bour S., Perrin C., Akari H., Strebel K. The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J. Biol. Chem. 2001;276:15920–15928. doi: 10.1074/jbc.M010533200. [DOI] [PubMed] [Google Scholar]
  6. Chowers M.Y., Spina C.A., Kwoh T.J., Fitch N.J., Richman D.D., Guatelli J.C. Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J. Virol. 1994;68:2906–2914. doi: 10.1128/jvi.68.5.2906-2914.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fenton-May A.E., Dibben O., Emmerich T., Ding H., Pfafferott K., Aasa-Chapman M.M., Pellegrino P., Williams I., Cohen M.S., Gao F., Shaw G.M., Hahn B.H., Ochsenbauer C., Kappes J.C., Borrow P. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology. 2013;10:146. doi: 10.1186/1742-4690-10-146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fiebig E.W., Wright D.J., Rawal B.D., Garrett P.E., Schumacher R.T., Peddada L., Heldebrant C., Smith R., Conrad A., Kleinman S.H., Busch M.P. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. Aids. 2003;17:1871–1879. doi: 10.1097/00002030-200309050-00005. [DOI] [PubMed] [Google Scholar]
  9. Galao R.P., Le Tortorec A., Pickering S., Kueck T., Neil S.J. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe. 2012;12:633–644. doi: 10.1016/j.chom.2012.10.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Garcia J.V., Miller A.D. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature. 1991;350:508–511. doi: 10.1038/350508a0. [DOI] [PubMed] [Google Scholar]
  11. Gillick K., Pollpeter D., Phalora P., Kim E.Y., Wolinsky S.M., Malim M.H. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol. 2013;87:1508–1517. doi: 10.1128/JVI.02587-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Haaland R.E., Hawkins P.A., Salazar-Gonzalez J., Johnson A., Tichacek A., Karita E., Manigart O., Mulenga J., Keele B.F., Shaw G.M., Hahn B.H., Allen S.A., Derdeyn C.A., Hunter E. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009;5:e1000274. doi: 10.1371/journal.ppat.1000274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Harris R.S., Hultquist J.F., Evans D.T. The restriction factors of human immunodeficiency virus. The Journal of Biol. Chem. 2012;287:40875–40883. doi: 10.1074/jbc.R112.416925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L., Brown W.L., Harris R.S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011;85:11220–11234. doi: 10.1128/JVI.05238-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kimura T., Nishikawa M., Ohyama A. Intracellular membrane traffic of human immunodeficiency virus type 1 envelope glycoproteins: vpu liberates Golgi-targeted gp160 from CD4-dependent retention in the endoplasmic reticulum. J. Biochem. 1994;115:1010–1020. doi: 10.1093/oxfordjournals.jbchem.a124414. [DOI] [PubMed] [Google Scholar]
  16. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe. 2010;8:55–67. doi: 10.1016/j.chom.2010.06.004. [DOI] [PubMed] [Google Scholar]
  17. Lama J., Mangasarian A., Trono D. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr. Biol. CB. 1999;9:622–631. doi: 10.1016/s0960-9822(99)80284-x. [DOI] [PubMed] [Google Scholar]
  18. Moll M., Andersson S.K., Smed-Sorensen A., Sandberg J.K. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood. 2010;116:1876–1884. doi: 10.1182/blood-2009-09-243667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008;451:425–430. doi: 10.1038/nature06553. [DOI] [PubMed] [Google Scholar]
  20. Ochsenbauer C., Edmonds T.G., Ding H., Keele B.F., Decker J., Salazar M.G., Salazar-Gonzalez J.F., Shattock R., Haynes B.F., Shaw G.M., Hahn B.H., Kappes J.C. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 2012;86:2715–2728. doi: 10.1128/JVI.06157-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Parker Z.F., Iyer S.S., Wilen C.B., Parrish N.F., Chikere K.C., Lee F.H., Didigu C.A., Berro R., Klasse P.J., Lee B., Moore J.P., Shaw G.M., Hahn B.H., Doms R.W. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J. Virol. 2013;87:2401–2411. doi: 10.1128/JVI.02964-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Parrish N.F., Gao F., Li H., Giorgi E.E., Barbian H.J., Parrish E.H., Zajic L., Iyer S.S., Decker J.M., Kumar A., Hora B., Berg A., Cai F., Hopper J., Denny T.N., Ding H., Ochsenbauer C., Kappes J.C., Galimidi R.P., West A.P., Jr., Bjorkman P.J., Wilen C.B., Doms R.W., O׳Brien M., Bhardwaj N., Borrow P., Haynes B.F., Muldoon M., Theiler J.P., Korber B., Shaw G.M., Hahn B.H. Vol. 110. 2013. Phenotypic properties of transmitted founder HIV-1; pp. 6626–6633. (Proc. Natl. Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H. HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. J. Virol. 2012;86:11712–11724. doi: 10.1128/JVI.00595-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pickering S., Hue S., Kim E.Y., Reddy S., Wolinsky S.M., Neil S.J. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog. 2014;10:e1003895. doi: 10.1371/journal.ppat.1003895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Redd A.D., Collinson-Streng A.N., Chatziandreou N., Mullis C.E., Laeyendecker O., Martens C., Ricklefs S., Kiwanuka N., Nyein P.H., Lutalo T., Grabowski M.K., Kong X., Manucci J., Sewankambo N., Wawer M.J., Gray R.H., Porcella S.F., Fauci A.S., Sagar M., Serwadda D., Quinn T.C. Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. J. Infect. Dis. 2012;206:1433–1442. doi: 10.1093/infdis/jis503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Salazar-Gonzalez J.F., Salazar M.G., Keele B.F., Learn G.H., Giorgi E.E., Li H., Decker J.M., Wang S., Baalwa J., Kraus M.H., Parrish N.F., Shaw K.S., Guffey M.B., Bar K.J., Davis K.L., Ochsenbauer-Jambor C., Kappes J.C., Saag M.S., Cohen M.S., Mulenga J., Derdeyn C.A., Allen S., Hunter E., Markowitz M., Hraber P., Perelson A.S., Bhattacharya T., Haynes B.F., Korber B.T., Hahn B.H., Shaw G.M. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 2009;206:1273–1289. doi: 10.1084/jem.20090378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sauter D., Hotter D., Engelhart S., Giehler F., Kieser A., Kubisch C., Kirchhoff F. A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release. Retrovirology. 2013;10:85. doi: 10.1186/1742-4690-10-85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sauter D., Hotter D., Van Driessche B., Sturzel C.M., Kluge S.F., Wildum S., Yu H., Baumann B., Wirth T., Plantier J.C., Leoz M., Hahn B.H., Van Lint C., Kirchhoff F. Differential regulation of NF-kappaB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell reports. 2015;10(4):586–599. doi: 10.1016/j.celrep.2014.12.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sauter D., Schindler M., Specht A., Landford W.N., Munch J., Kim K.A., Votteler J., Schubert U., Bibollet-Ruche F., Keele B.F., Takehisa J., Ogando Y., Ochsenbauer C., Kappes J.C., Ayouba A., Peeters M., Learn G.H., Shaw G., Sharp P.M., Bieniasz P., Hahn B.H., Hatziioannou T., Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe. 2009;6:409–421. doi: 10.1016/j.chom.2009.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schwartz O., Marechal V., Le Gall S., Lemonnier F., Heard J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 1996;2:338–342. doi: 10.1038/nm0396-338. [DOI] [PubMed] [Google Scholar]
  31. Shah A.H., Sowrirajan B., Davis Z.B., Ward J.P., Campbell E.M., Planelles V., Barker E. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe. 2010;8:397–409. doi: 10.1016/j.chom.2010.10.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–650. doi: 10.1038/nature00939. [DOI] [PubMed] [Google Scholar]
  33. Swigut T., Shohdy N., Skowronski J. Mechanism for down-regulation of CD28 by Nef. The EMBO J. 2001;20:1593–1604. doi: 10.1093/emboj/20.7.1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The Interferon-Induced Protein BST-2 Restricts HIV-1 Release and Is Downregulated from the Cell Surface by the Viral Vpu Protein. Cell Host Microbe. 2008;3:245–252. doi: 10.1016/j.chom.2008.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wildum S., Schindler M., Munch J., Kirchhoff F. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J. Virol. 2006;80:8047–8059. doi: 10.1128/JVI.00252-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wilen C.B., Parrish N.F., Pfaff J.M., Decker J.M., Henning E.A., Haim H., Petersen J.E., Wojcechowskyj J.A., Sodroski J., Haynes B.F., Montefiori D.C., Tilton J.C., Shaw G.M., Hahn B.H., Doms R.W. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 2011;85:8514–8527. doi: 10.1128/JVI.00736-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 2004;78:6073–6076. doi: 10.1128/JVI.78.11.6073-6076.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1: amino acid alignment of Vpu alleles used in this study.

mmc1.doc (49.9KB, doc)

Supplementary Figure 2: amino acid alignment of Vif alleles used in this study

mmc2.doc (85.8KB, doc)

Supplementary Figure 3: amino acid alignment of Nef alleles used in this study

mmc3.doc (97KB, doc)

RESOURCES